Breaking News Instant updates and real-time market news.

NVS

Novartis

$80.72

-0.42 (-0.52%)

, JUNO

Juno Therapeutics

$21.68

-0.68 (-3.04%)

11:37
06/12/17
06/12
11:37
06/12/17
11:37

Novartis CAR-T trial terminated due to 'lack of efficacy'

According to a post to ClinicalTrials.gov, a pilot study of autologous anti-CD22 Chimeric Antigen Receptor Redirected T Cells in patients with chemotherapy resistant or refractory acute lymphoblastic leukemia sponsored by the University of Pennsylvania was terminated "due to lack of efficacy." The trial has been identified as being conducted in partnership with Novartis (NVS). Other companies exploring CAR-T treatments of cancer include bluebird bio (BLUE), Juno Therapeutics (JUNO) and Kite Pharma (KITE). Reference Link

NVS

Novartis

$80.72

-0.42 (-0.52%)

JUNO

Juno Therapeutics

$21.68

-0.68 (-3.04%)

BLUE

bluebird bio

$111.90

0.9 (0.81%)

KITE

Acquired by GILD 9/17

$87.79

1.12 (1.29%)

  • 13

    Jun

  • 19

    Jun

  • 20

    Jun

  • 22

    Jun

  • 26

    Jun

  • 29

    Nov

NVS Novartis
$80.72

-0.42 (-0.52%)

06/08/17
06/08/17
UPGRADE
Target $100

Buy
Kite Pharma upgraded to Buy on Axi-Cel manufacturing edge at BTIG
As previously reported, BTIG analyst Dane Leone upgraded Kite Pharma (KITE) to Buy from Neutral and set a $100 price target on the shares. Data from Novartis (NVS) and Juno (JUNO) have failed to deliver any recognizable differentiation, though Leone gives Kite "a clear win" for the manufacturing of Axi-Cel versus peers, he tells investors. The analyst sees Kite having the cleanest pathway to approval for diffuse large B-cell lymphoma and, given Kite's manufacturing edge, he estimates that Axi-Cel can take about 60% of share within the U.S. DLBCL market.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/06/17
LEER
06/06/17
NO CHANGE
Target $100
LEER
Outperform
bluebird data among most impressive in CAR-T space, says Leerink
Leerink analyst Michael Schmidt says bluebird bio's (BLUE) bb2121 dose-escalation data in multiple myeloma is among the most impressive early data sets he's seen in the CAR-T space to date. The data sets a high bar for the competition, which includes Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS), Schmidt tells investors in a research note. Being one year ahead of the competition provides bluebird and Celgene (CELG) with an ideal position in multiple myeloma, the analyst adds. He keeps an Outperform rating on bluebird shares with a $100 price target.
06/01/17
NEED
06/01/17
NO CHANGE
Target $4.5
NEED
Buy
Cryoport price target raised to $4.50 from $3.50 at Needham
Needham analyst Sean Hannan noted that Novartis (NVS) and Kite Pharma (KITE) both have Biologics License Applications nearing approval for studies believed to be supported by Cryoport (CYRX). Citing his growing comfort on clients' progress toward commercialization, he raised his price target on Cryoport to $4.50 from $3.50 and keeps a Buy rating on the "arms provider" to companies working on emerging regenerative therapies.
JUNO Juno Therapeutics
$21.68

-0.68 (-3.04%)

06/08/17
BTIG
06/08/17
DOWNGRADE
BTIG
Sell
Juno downgraded on lateness to market, lack of differentiation at BTIG
As noted earlier, BTIG downgraded Juno to Sell from Neutral. Analyst Dane Leone says that the company's treatment for CD19 and hematologic malignancies is on track to hit the market later than competing products, while there is no "demonstrated proof" that Juno will have any advantages in the areas of efficacy or toxicity. The analyst expects the revenue generated by Juno's JCAR017 treatment to come in about $1B below consensus expectations through 2026. Target $12.
06/08/17
06/08/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Juno Therapeutics (JUNO) downgraded to Sell from Neutral at BTIG with analyst Dane Leone saying that the company's treatment for CD19 and hematologic malignancies is on track to hit the market later than competing products, while there is no "demonstrated proof" that Juno will have any advantages in the areas of efficacy or toxicity. 2. National Grid (NGG) downgraded to Sell from Hold at Deutsche Bank with analyst James Brand saying the company's sustainable equity cash flow yield could drop below 6% after its next regulatory review. 3. BHP Billiton (BHP) downgraded to Hold from Buy at Jefferies with analyst Christopher LaFemina saying he believes the balance sheet recap trade in mining as well as the Chinese stimulus-driven recovery in demand is over. 4. Lear (LEA) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he expects Lear's earnings to peak this year and to fall by 20% by 2021 and expects Electrical business margins to disappoint investors due to higher development costs, increased competition, and potential lost market share. 5. Hawaiian Holdings (HA) downgraded to Hold from Buy at Deutsche Bank with analyst Michael Linenberg saying the valuation is near full following the recent rally. The analyst raised his price target for the shares to $64 from $63. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/17
BTIG
06/08/17
DOWNGRADE
BTIG
Sell
Juno Therapeutics downgraded to Sell from Neutral at BTIG
BLUE bluebird bio
$111.90

0.9 (0.81%)

06/07/17
JANY
06/07/17
NO CHANGE
Target $125
JANY
Buy
bluebird bio price target raised to $125 after new CAR-T data at Janney Capital
Janney Capital analyst Debjit Chattopadhyay raised his fair value estimate for bluebird bio shares to $125 from $81 citing the company's BCMA-targeted CAR-T data. After the presentation of updated results from a Phase 1 study of bb2121 in 18 patients with relapsed/refractory multiple myeloma, Chattopadhyay noted that responses are "deep and sustained," patients can be potentially retreated on relapse, CRS events are manageable and neurotoxicity has yet to manifest. Data from bluebird and Nanjing Legend leads the analyst to believe CAR-T therapies could rival autologous stem cell transplants in multiple myeloma, he tells investors. Chattopadhyay keeps a Buy rating on bluebird bio shares.
06/06/17
06/06/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Cabot Oil & Gas (COG) upgraded to Outperform from Neutral at Macquarie with analyst Paul Grigel saying the pullback in shares is overdone and expects improved Natural Gas prices into the fall and tighter Marcellus differentials. 2. Dunkin' Brands (DNKN) upgraded to Buy from Hold at Argus with analyst John Staszak saying that the company, unlike most restaurant chains he covers, has "strong opportunities to expand its brand both in the U.S. and internationally." 3. bluebird bio (BLUE) upgraded to Outperform from Market Perform at BMO Capital with analyst Matthew Luchini saying that a trial of the company's bb2121 drug showed that its efficacy is "compelling," while its safety is "generally clean." 4. Paccar (PCAR) upgraded to Buy from Neutral at UBS with analyst Steven Fisher saying he expects truck production to inflect positively in the next 12 months, which should drive upside to earnings estimates. 5. Tenet (THC) upgraded to Outperform from Market Perform at Wells Fargo with analyst Gary Lieberman saying the sale of additional hospitals to HCA Holdings (HCA) could drive shares up 30%-40%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/17
BMOC
06/06/17
UPGRADE
BMOC
Outperform
bluebird bio upgraded on data at BMO Capital
As noted earlier, BMO Capital upgraded bluebird bio to Outperform from Market Perform. Analyst Matthew Luchini says that a trial of the company's bb2121 drug showed that its efficacy is "compelling," while its safety is "generally clean." Target to $108 from $83.
06/06/17
RHCO
06/06/17
NO CHANGE
RHCO
bluebird bio data 'impressive,' says SunTrust
SunTrust analyst Edward Nash says that the data for the Phase I trial of bluebird's bb2121 in relapsed/refractory multiple myeloma.was "impressive." He says that the drug's efficacy was "robust," while its safety appears to be "manageable." The analyst keeps a $108 price target and Buy rating on the stock.
KITE Acquired by GILD 9/17
$87.79

1.12 (1.29%)

06/08/17
06/08/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AutoNation (AN) upgraded to Buy from Neutral at Northcoast. 2. Kite Pharma (KITE) upgraded to Buy from Neutral at BTIG with analyst Dane Leone saying data from Novartis (NVS) and Juno (JUNO) have failed to deliver any recognizable differentiation, though Leone gives Kite "a clear win" for the manufacturing of Axi-Cel versus peers. 3. Infosys (INFY) upgraded to Buy from Hold at HSBC with analyst Yogesh Aggarwal citing "undemanding" valuation and low expectations. 4. DSW (DSW) upgraded to Neutral from Underperform at Cleveland Research. 5. BHP Billiton (BHP) upgraded to Buy from Neutral at UBS with analyst Glyn Lawcock citing its current valuation, attractive yield, and upcoming catalysts that include asset disposals, approval of the attractive Spence Growth Option, and expectations for a new chairman in the near-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/17
BTIG
06/08/17
UPGRADE
BTIG
Buy
Kite Pharma upgraded to Buy from Neutral at BTIG

TODAY'S FREE FLY STORIES

09:42
11/24/17
11/24
09:42
11/24/17
09:42
General news
S&P 500 rises to all time high at start of holiday-shortened session »

Investors returning from…

STAG

STAG Industrial

09:41
11/24/17
11/24
09:41
11/24/17
09:41
Conference/Events
STAG Industrial management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 14

    Dec

ETE

Energy Transfer Equity

, QCOM

Qualcomm

$68.13

1.46 (2.19%)

09:40
11/24/17
11/24
09:40
11/24/17
09:40
Options
Unusually active option classes on open November 24th »

Unusual total active…

ETE

Energy Transfer Equity

QCOM

Qualcomm

$68.13

1.46 (2.19%)

TEVA

Teva

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

COP

ConocoPhillips

09:39
11/24/17
11/24
09:39
11/24/17
09:39
Conference/Events
ConocoPhillips management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

QD

Qudian

09:37
11/24/17
11/24
09:37
11/24/17
09:37
Recommendations
Qudian analyst commentary  »

Qudian price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

09:37
11/24/17
11/24
09:37
11/24/17
09:37
Conference/Events
MetLife management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 15

    Dec

SOLVY

Solvay

09:35
11/24/17
11/24
09:35
11/24/17
09:35
Conference/Events
Solvay management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

SPY

SPDR S&P 500 ETF Trust

, SPX

S&P 500

09:34
11/24/17
11/24
09:34
11/24/17
09:34
Technical Analysis
Technical View: S&P 500 edges new life high, pivot high broken »

The S&P 500 (SPX) was…

SPY

SPDR S&P 500 ETF Trust

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRFS

Grifols

$23.04

-0.13 (-0.56%)

09:33
11/24/17
11/24
09:33
11/24/17
09:33
Downgrade
Grifols rating change  »

Grifols downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMA

Banco Macro

09:32
11/24/17
11/24
09:32
11/24/17
09:32
Downgrade
Banco Macro rating change  »

Banco Macro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSU

Tim Participacoes

09:32
11/24/17
11/24
09:32
11/24/17
09:32
Upgrade
Tim Participacoes rating change  »

Tim Participacoes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
11/24/17
11/24
09:30
11/24/17
09:30
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

November PMI Composite…

09:30
11/24/17
11/24
09:30
11/24/17
09:30
General news
PMI Composite Flash Manufacturing â€' Level to be reported at 09:45 »

November PMI Composite…

DSX

Diana Shipping

09:25
11/24/17
11/24
09:25
11/24/17
09:25
Hot Stocks
Diana Shipping announces time charter contract for m/v Norfolk »

Diana Shipping announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAUR

Laureate Education

$11.63

0.22 (1.93%)

09:25
11/24/17
11/24
09:25
11/24/17
09:25
Recommendations
Laureate Education analyst commentary  »

Laureate received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$41.01

4.31 (11.74%)

09:23
11/24/17
11/24
09:23
11/24/17
09:23
Recommendations
Copart analyst commentary  »

Copart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
11/24/17
11/24
09:18
11/24/17
09:18
Options
Overnight activity included 97 trades in SPX and 9 trades in VIX »

97 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRAX

Social Reality

$5.82

1.59 (37.59%)

09:14
11/24/17
11/24
09:14
11/24/17
09:14
Technical Analysis
Technical View: Social Reality trades sharply higher in pre-market »

At time of writing the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXC

Exelon

09:10
11/24/17
11/24
09:10
11/24/17
09:10
Conference/Events
Exelon management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

PN

Patriot National

09:10
11/24/17
11/24
09:10
11/24/17
09:10
Hot Stocks
Breaking Hot Stocks news story on Patriot National »

Patriot National trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$13.48

0.15 (1.13%)

, QD

Qudian

$16.15

-3.16 (-16.36%)

09:09
11/24/17
11/24
09:09
11/24/17
09:09
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Teva…

TEVA

Teva

$13.48

0.15 (1.13%)

QD

Qudian

$16.15

-3.16 (-16.36%)

RYB

RYB Education

$26.71

-1.1 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

CLSN

Celsion

$3.13

0.27 (9.44%)

09:06
11/24/17
11/24
09:06
11/24/17
09:06
Technical Analysis
Technical View: Celsion trades sharply higher in pre-market »

At time of writing in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$16.15

-3.16 (-16.36%)

09:01
11/24/17
11/24
09:01
11/24/17
09:01
Technical Analysis
Technical View: Qudian drops to new low »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$26.66

-0.07 (-0.26%)

, VRX

Valeant

$16.54

0.55 (3.44%)

08:55
11/24/17
11/24
08:55
11/24/17
08:55
Options
Notable open interest changes for November 24th »

Wednesday's total…

BAC

Bank of America

$26.66

-0.07 (-0.26%)

VRX

Valeant

$16.54

0.55 (3.44%)

SQ

Square

$48.81

0.75 (1.56%)

MSFT

Microsoft

$83.11

-0.61 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 14

    Dec

  • 18

    Jun

08:55
11/24/17
11/24
08:55
11/24/17
08:55
General news
U.S. equity futures are firmer »

U.S. equity futures are…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.